OverviewSuggest Edit

Bioskryb is a company bringing solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system. Its technology enables coverage of the entire genome during DNA amplification and allows for accuracy and uniformity in DNA sequence coverage and base calling – the identification of the individual DNA bases.


Latest Updates

Employees (est.) (Sept 2021)31(+4%)

Key People/Management at BioSkryb

Jay West

Jay West

CEO / Co-Founder and Board Member
Charles Gawad

Charles Gawad

Director / Co-Founder
Wendi Carter

Wendi Carter

VP of Accounting and Finance
Debrah Herman

Debrah Herman

Anne Vrolyk

Anne Vrolyk

VP of Business Development
Rob Carter

Rob Carter

Director of Bioinformatics
Show more

BioSkryb Financials and Metrics

Summary Metrics

Founding Date


BioSkryb total Funding

$11.5 m

BioSkryb latest funding size

$11.5 m

Time since last funding

2 years ago

BioSkryb investors

BioSkryb's latest funding round in January 2020 was reported to be $11.5 m. In total, BioSkryb has raised $11.5 m
Show all financial metrics

BioSkryb Online and Social Media Presence

Embed Graph

BioSkryb News and Updates

BioSkryb Launches Researcher Early Access Program for Genomic Amplification Technology

DURHAM, N.C., Aug. 3, 2020 /PRNewswire/ -- BioSkryb, Inc. ("BioSkryb"), a developer of genomic amplification technologies that deliver higher coverage and fidelity for gene sequencing, today announced that it has launched an Early Access Program (EAP) for researchers to test its...

BioSkryb Blogs

Meet BioSkryb’s New Commercial Team Members Providing Customer Care and Technical Support

Meet BioSkryb's New Commercial Team Members We are excited to welcome three new team members who bring deep scientific knowledge as well as technical experience in supporting researcher needs in applying new genomic and molecular biology solutions. “Just as we know each cell is unique, so are our pe…

In-depth empowerment and innovation! 2021 MGI & IDG Capital Life and Health Acceleration Camp officially opens

July 31 - Huatai Zhi made (MGI), IDG investment Innovation Institute and Blue Rainbow Life Sciences Accelerator jointly organized by the MGI & IDG capital accelerated life and health business (hereinafter referred to as "accelerated Camp") in the Nanshan District, Shenzhen, IDG Capital Innovatio…

BioSkryb Appoints Gary Harton, Ph.D., Chief Scientific Officer

BioSkryb Appoints Gary Harton, Ph.D., Chief Scientific Officer Dr. Harton to lead the translation of BioSkryb’s Primary Template-directed Amplification (PTA) technology into breakthrough diagnostic applications for targeted indications, including cancer and neurological disorders DURHAM, N.C., June …

BioSkryb Appoints Sean Keohane Senior Vice President of Commercial Operations

Keohane to spearhead commercialization of BioSkryb’s ResolveDNATM suite of products for high-quality single-cell whole genome amplification DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb, Inc., today announced the expansion of the company’s leadership team with the appointment of Sean Keohane as Senior Vic…

Top 10 BioTech Industry Trends & Innovations in 2021

The BioTech industry is adopting trends like artificial intelligence (AI), data analytics, and automation to optimize production. Consequently, there has been a rise in consumer BioTech or BioTech products targeted directly at customers instead of biopharma or healthcare businesses. While the indust…

BioSkryb Announces the Winners of Its Grant Program to Aid Research Using Primary Template-directed Amplification Technology

DURHAM, N.C.--(BUSINESS WIRE)--Today, at the Advances in Genome Biology and Technology (AGBT) 2021 General Meeting held virtually, BioSkryb, Inc., a developer of genomic amplification technologies, announced the winners of a research grant program sponsored by the company. The grant program was crea…
Show more

BioSkryb Frequently Asked Questions

  • When was BioSkryb founded?

    BioSkryb was founded in 2018.

  • Who are BioSkryb key executives?

    BioSkryb's key executives are Jay West, Charles Gawad and Wendi Carter.

  • How many employees does BioSkryb have?

    BioSkryb has 31 employees.

  • Who are BioSkryb competitors?

    Competitors of BioSkryb include Crioestaminal, ProteinSimple and Jackson ImmunoResearch.